About the LVAD

The LVAD pulls blood from the left ventricle into a pump. The pump then sends blood into the aorta (the large blood vessel leaving the left ventricle). This helps the weakened ventricle and takes over its pumping action. The pump is placed in the chest and the wires for the battery and the controller exit from upper part of abdomen, to the outside of the body and attached to the pump's battery and control system.


LVADs are now portable and can be used for many years. Patients with LVADs can be discharged from the hospital, return to their normal activities and enjoy a good quality of life while waiting for a donor heart to become available. Destination therapy patients, who are not transplant candidates, can also enjoy this same quality of life for years after implantation.

Who can get a LVAD?

For a patient to receive a LVAD, they need to have a heart sick enough to need one, but must not be too sick overall—otherwise the LVAD is too risky. To determine whether the heart is sick enough, and whether the rest of the body in in good enough shape. we perform a number of objective tests.

When the evaluation has finished, your cardiologist will present your case to the LVAD/heart transplant selection committee. The committee meets weekly to determine whether LVAD is the right therapy for you.


NASA Invention of the Year

HA5 cut away

The NASA invention of the year is awarded by the NASA office of General Counsel in partnership with the NASA inventions and Contributions Board. There have been 1,800 spins off and twelve have won the invention of the year award. The invention of the year award recognizes inventions of exceptional NASA cutting edge technologies that have been patented in the United States.

The HeartAssist is CE marked in Europe for patients awaiting transplant or for patients that will receive the tiny pump as a permanent flow assist. In the United States, the HeartAssist5® has been approved by the FDA for a Bridge to Transplant Investigational Device Exemption (IDE) trial.



The HeartAssist includes features such as FlowAccurate™ Diagnostics (direct blood flow measurement) available world-wide through our HeartAssistRemote™ Monitoring System. These exclusive features are available today only with the HeartAssist5®.

However, the true test for any LVAD is how well it matches the needs of the human heart it is assisting.

Promising results from implants of the new HeartAssist5® in Europe have begun to generate peer reviewed posters, presentations and papers documenting its performance. As these reports become available, ReliantHeart will distribute the findings, which we believe will document better results, and lower complications and side effects.

Smallest Size and Weight

  Cropped Pyramid

The pump weighs only 92 grams, and is nearly silent.

The new HeartAssist VAD supports extra large adults to pediatric patients as small as 18 kg. It provides smooth, gentle blood flow from 2-10 L/min. For weaning patients whose own hearts are recovering, the HeartAssist provides precise blood flow as low as 2 L/min.

The HeartAssist’s small size is also one of the features that led to FDA approval as a Humanitarian Device Exemption (HDE) for use in pediatric patients in the United States. This indication is also CE Mark Approved for Europe. The HeartAssist5® can be implanted in children as young as four to six years old with a body surface area of 0.7m2 or larger.

VAD_Size_Comparison ha5-blue_us-med

The New Intraventricular aVAD™

 A new intraventricular heart pump has made its debut.

Small outside at 2.48 centimeters in diameter and BIG inside with a 1.2 centimeter diameter flow tube. Deep linear channels transport blood safely through the pump away from the dangerous forces of radial shear. And the FastConnect system provides for adjustable pump depth inside the ventricle.aVAD heart image2

A modern approach to power management has produced generous start and running torque at 30% of the power consumption of other VADs. Batteries are smaller and last longer.

The intraventricular implant of the aVAD™ may facilitate a less invasive surgical technique.

The modern technology of TrueFlow measurement and 24/7 remote monitoring of TrueFlow, Speed and Power provide a sentinel system for early alert. For example TrueFlow and the Amplitude of TrueFlow can provide early warning of patterns of dehydration or atrial fibrillation.

Remote monitoring thrives on a modern world wide 3G Communication system carried seamlessly over 450 networks. Remote monitoring is in real time, all the time from anywhere.

ReliantHeart is currently designing a disconnectable cable for use with the aVAD™, making it forward compatible with a Transcutaneous Energy Transfer system (TET) under development at ReliantHeart; the Liberty system. LibertyTET is a power supply method that allows for power and data to be transmitted across the skin without the need for a wire exiting through the skin. Patients with an aVAD™ will be upgradable to the Liberty system in 2018.


FlowAccurate™ Diagnostics


HeartAssistRemote™ Monitoring


Benefits Include:

  • Improves Clinical Efficiency
  • Enables Earlier Patient Intervention
  • Enhances Patient Convenience
  • Leverages Limited Staff and Health Care Resources

The HeartAttendant® is the all-in-one Portable in Hospital Console for the HeartAssist5®


  • Shows real time blood flow data
  • Transmits blood flow and related data via secure wireless Internet for remote home monitoring via computers, or smartphones
  • 21cm diagonal color touch screen display
  • Sturdy all-in-one portable console
Stages of Heart Failure

Heart failure is chronic and progressive. Based on your symptoms and quality of life, the progression of heart failure is divided into four classes by the New York Heart Association.

Advanced Heart Failure


As heart failure progresses, medications and surgery may no longer be adequate to manage this condition. These patients may benefit from a mechanical circulatory support device, such as a Left Ventricular Assist Device (LVAD).

Our Partners